PARIS–(BUSINESS WIRE)–Regulatory news:
EUROAPI (Paris:EAPI) today published its 2022 condensed half-year consolidated financial statements for the half-year ended June 30, 2022. This document is available for consultation and download on the EUROAPI website: https://www.europapi.com/en/investors/regulatory-information/financial-reports.
This report includes in particular the 2022 half-year activity report, the condensed consolidated financial statements as of June 30, 2022 and the limited review report of the statutory auditors on the 2022 half-year financial information.
EUROAPI is focused on reinventing active ingredient solutions to sustainably meet the needs of customers and patients around the world. We are a major player in active pharmaceutical ingredients with approximately 200 products in our portfolio, offering a wide range of technologies, while developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO) activities.
Acting for health by providing access to essential therapies inspires our 3,350 people every day. With strong research and development capabilities and six manufacturing sites all located in Europe, EUROAPI ensures the highest quality API manufacturing to supply customers in over 80 countries. EUROAPI is listed on Euronext Paris; ISIN: FR0014008VX5; code: EAPI). Learn more about www.eurapi.com and follow us on LinkedIn.